Sol-Gel Technologies Provides Program Update for TWIN for the Treatment of Acne Vulgaris
Announces Positive End-of-Phase II Meeting with the
Receives Special Protocol Assessment (SPA) Agreement from
Company expects to commence the TWIN Phase III clinical trials in the fourth quarter of 2018 with top-line data expected in 2019
NESS ZIONA,
As a result, the Company reiterates its prior guidance that it expects to commence the pivotal Phase III clinical trials for TWIN in the fourth quarter of 2018. The Company expects to report top-line data from the Phase III clinical program in 2019.
Based on the FDA’s feedback provided in the minutes of the End-of-Phase II meeting and the associated SPA agreement, key elements of the Phase III program are:
- Only the TWIN and vehicle cream (placebo) arms are required for the Phase III clinical trials, as the requirements of the combination rule act were satisfied in our Phase II trial.
- Each of the two TWIN Phase III clinical trials will consist of approximately 420 subjects aged 9 and above, with a power of 99%.
- No pediatric clinical studies are required to support our future marketing application.
- No long-term safety study will be required to support our marketing application, as long as we demonstrate that the systemic exposure of our product is comparable to our reference-listed drug (RLD).
“The combination of the positive End-of-Phase II meeting coupled with the SPA helps to clearly define the regulatory path for TWIN,” commented Dr.
An updated Corporate Presentation may be viewed at: http://ir.sol-gel.com/events-and-presentations.
About Special Protocol Assessment (SPA)
SPA is a process in which sponsors may ask to meet with
About TWIN
TWIN is a novel non-antibiotic topical cream for the treatment of acne vulgaris that is designed to be tolerable and highly effective. TWIN is the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin, which are separately encapsulated in silica using our proprietary technology. Tretinoin and benzoyl peroxide are widely believed to be effective as a combination treatment for acne. The silica microcapsule protects tretinoin from oxidative decomposition by benzoyl peroxide, thereby enhancing the stability and shelf-life of the product. The silica shell also creates a barrier between the drug substances and the skin and as a result is expected to reduce irritation typically associated with topical application of benzoyl peroxide and tretinoin, thereby increasing the tolerability of TWIN on acne-affected skin.
About Acne Vulgaris
Acne vulgaris is a common multifactorial skin disease that according to the American Academy of Dermatology affects approximately 40 to 50 million people in the
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the commencement of our planned clinical trials for TWIN, the commencement of our planned bioequivalence study for a generic product candidate and our expected date to report top-line data from our pivotal Phase III clinical program for Epsolay® and TWIN. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statement, including but not limited to, the following: the fact that we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our ability to complete the development of our product candidates; our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; our ability to rely on data from our Phase II TWIN trial to advance the development of SIRS-T; our ability to commercialize our product candidates; our ability to obtain and maintain adequate protection of our intellectual property; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; acceptance of our product candidates by healthcare professionals and patients; the possibility that we may face third-party claims of intellectual property infringement; the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; potential product liability claims; potential adverse federal, state and local government regulation in
For further information, please contact:
Sol-Gel Contact:
Chief Financial Officer
+972-8-9313433
Investor Contact:
Westwicke Partners
+1-415-513-1284
[email protected]
Source: Sol-Gel Technologies Ltd.